1416 Results

People

  1. Motzer
    Motzer
  2. Vickers
    Vickers
  3. Hudis
    Hudis
  4. Norton
    Norton
  5. Saltz
    Saltz
  6. O'Reilly
    O'Reilly
  7. Mao
    Mao
  8. Morris
    Morris
  9. Seidman
    Seidman
  10. Kris
    Kris

Groups

  1. Department of Medicine (753)
  2. Solid Tumor Oncology Division (541)
  3. Population Sciences Research Program (259)
  4. Survivorship Research (256)
  5. Surgery (244)
  6. Epidemiology and Biostatistics (187)
  7. Hematologic Malignancies, Division of (169)
  8. Genitourinary Oncology Service (160)
  9. Center for Hematologic Malignancies (142)
  10. Gastrointestinal Oncology Service (126)
  1. "randomized controlled trial"
Formats
  1. Journal Article (1353)
  2. Review (19)
  3. Conference Paper (17)
  4. Editorial (9)
  5. Correspondence (5)
  6. Research Letter (5)
  7. Meeting Abstract (4)
  8. Guidelines (3)
  9. Book Section (1)
Groups
  1. Department of Medicine (753)
  2. Solid Tumor Oncology Division (541)
  3. Population Sciences Research Program (259)
  4. Survivorship Research (256)
  5. Surgery (244)
  6. Epidemiology and Biostatistics (187)

More Groups

People
  1. Robert Motzer (83)
  2. Andrew Vickers (48)
  3. Larry Norton (34)
  4. Clifford Hudis (33)
  5. Leonard Saltz (32)
  6. Eileen O'Reilly (25)

More People

Years
  1. 2025 (63)
  2. 2024 (165)
  3. 2023 (110)
  4. 2022 (81)
  5. 2021 (39)
  6. 2020 (51)

More Years

Publications
  1. Journal of Clinical Oncology (164)
  2. New England Journal of Medicine (65)
  3. Lancet Oncology (46)
  4. Cancer (42)
  5. Clinical Cancer Research (42)
  6. European Urology (26)

More Publications

Publishers
  1. Elsevier Inc. (187)
  2. American Society of Clinical Oncology (170)
  3. Elsevier Science, Inc. (138)
  4. Springer (79)
  5. Lippincott Williams & Wilkins (72)
  6. Wiley Blackwell (71)

More Publishers

Results (1416)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Improving breast cancer surgical treatment decision making: The iCanDecide randomized clinical trial
    Journal Article

    Hawley, S. T.; Li, Y.; An, L. C.; Resnicow, K.; Janz, N. K.; Sabel, M. S.; Ward, K. C.; Fagerlin, A.; Morrow, M.; Jagsi, R.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: Crossover of a phase 3 study
    Journal Article

    Molina, A. M.; Hutson, T. E.; Nosov, D.; Tomczak, P.; Lipatov, O.; Sternberg, C. N.; Motzer, R.; Eisen, T.
    European Journal of Cancer (2018)

    Fulltext@MSK | Save
  • No evidence of increase in calcitonin concentrations or development of C-cellmalignancy in response to liraglutide for up to 5 years in the LEADER trial
    Journal Article

    Hegedüs, L.; Sherman, S. I.; Tuttle, R. M.; von Scholten, B. J.; Rasmussen, S.; Karsbøl, J. D.; Daniels, G. H.; for the LEADER Publication Committee on behalf of the LEADER Trial Investigators
    Diabetes Care (2018)

    Fulltext@MSK | Save
  • Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: Retrospective observational study
    Journal Article

    Wagner, J.; Marquart, J.; Ruby, J.; Lammers, A.; Mailankody, S.; Kaestner, V.; Prasad, V.
    BMJ: British Medical Journal (International Edition) (2018)

    Fulltext@MSK | Save
  • Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma
    Journal Article

    Horwitz, S. M.; Koch, R.; Porcu, P.; Oki, Y.; Moskowitz, A.; Perez, M.; Myskowski, P.; Officer, A.; Jaffe, J. D.; Morrow, S. N.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma
    Journal Article

    Connors, J. M.; Jurczak, W.; Straus, D. J.; Ansell, S. M.; Kim, W. S.; Gallamini, A.; Younes, A.; Alekseev, S.; Illés, Á.; Picardi, M.; more...
    New England Journal of Medicine (2018)

    Fulltext@MSK | Save
  • Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: A comparison with prostate-specific antigen across five randomized phase III clinical trials
    Journal Article

    Heller, G.; McCormack, R.; Kheoh, T.; Molina, A.; Smith, M. R.; Dreicer, R.; Saad, F.; de Wit, R.; Aftab, D. T.; Hirmand, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: A randomized, controlled, open-label phase III trial
    Journal Article

    Larkin, J.; Minor, D.; D'Angelo, S.; Neyns, B.; Smylie, M.; Miller, W. H. Jr; Gutzmer, R.; Linette, G.; Chmielowski, B.; Lao, C. D.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: Results of a phase I dose-escalation and expansion study
    Journal Article

    Sullivan, R. J.; Infante, J. R.; Janku, F.; Lee Wong, D. J.; Sosman, J. A.; Keedy, V.; Patel, M. R.; Shapiro, G. I.; Mier, J. W.; Tolcher, A. W.; more...
    Cancer Discovery (2018)

    Fulltext@MSK | Save
  • Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: Results from the randomized BFORE trial
    Journal Article

    Cortes, J. E.; Gambacorti-Passerini, C.; Deininger, M. W.; Mauro, M. J.; Chuah, C.; Kim, D. W.; Dyagil, I.; Glushko, N.; Milojkovic, D.; le Coutre, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save